Medications

Tabrecta gains full FDA approval for non-small cell lung cancer

The U.S. Food and Drug Administration granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a genetic mutation leading to mesenchymal-epithelial ...

Oncology & Cancer

Blood test predicts response to immunotherapy

A blood-based tumor biomarker can predict the benefit of immunotherapy to patients with non-small cell lung cancer, according to a study published in Nature Medicine.

page 2 from 13